Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P51690

UPID:
ARSL_HUMAN

ALTERNATIVE NAMES:
Arylsulfatase E

ALTERNATIVE UPACC:
P51690; Q53FT2; Q53FU8

BACKGROUND:
Arylsulfatase L, with alternative naming as Arylsulfatase E, is identified for its arylsulfatase activity towards specific substrates, playing an essential role in the mineralization and development of bone and cartilage. Its activity is critical for maintaining the structural integrity of these tissues during development.

THERAPEUTIC SIGNIFICANCE:
The protein's malfunction is directly associated with Chondrodysplasia punctata 1, X-linked recessive, a genetic disorder affecting bone and cartilage. The elucidation of Arylsulfatase L's function offers a promising avenue for therapeutic intervention in diseases related to bone and cartilage malformation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.